CRNN: A Potential Drug Target and Biomarker for Calcium Homeostasis

Target Name: CRNN

NCBI ID: G49860

CRNN

CRNN: A Potential Drug Target and Biomarker for Calcium Homeostasis

Abstract:

Calcium homeostasis is a crucial physiological process that regulates various cellular functions, including muscle contractions, nerve impulse transmission, and cell signaling. The Ca2+-ATPase CRNN (53 kDa putative calcium-binding protein) is an essential protein that plays a significant role in maintaining calcium homeostasis. In this article, we discuss the potential implications of CRNN as a drug target and biomarker for calcium homeostasis.

Introduction:

Calcium homeostasis is a critical process that involves various cellular functions, including muscle contractions, nerve impulse transmission, and cell signaling. The regulation of calcium homeostasis is crucial for maintaining cellular function and survival. The Ca2+-ATPase CRNN (53 kDa putative calcium-binding protein) is an essential protein that plays a significant role in maintaining calcium homeostasis.

CRNN: A Potential Drug Target:

The Ca2+-ATPase CRNN is a protein that is expressed in various tissues, including muscle, nerve, and heart. It is a key component of the calcium homeostasis system, as it enables the regulation of calcium ions (Ca2+) in the cytosol. The CRNN protein has a molecular weight of 53 kDa and is expressed in different cellular types.

The CRNN protein is involved in several critical cellular processes, including muscle contractions, nerve impulse transmission, and cell signaling. It plays a crucial role in regulating the levels of calcium ions in the cytosol, which are essential for various cellular functions. is known to interact with several other proteins, including the calbindin protein (CaBP), which is also involved in maintaining calcium homeostasis.

The potential implications of CRNN as a drug target are significant. CRNN has been shown to be a promising drug target for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. By targeting CRNN, researchers could potentially develop new treatments for these diseases.

CRNN as a Biomarker:

In addition to its potential as a drug target, CRNN may also be a useful biomarker for the diagnosis and monitoring of various diseases. The Ca2+-ATPase CRNN is expressed in various tissues and is involved in several critical cellular processes. Therefore, changes in the levels of CRNN could be an indicator of certain diseases.

Research has shown that CRNN levels are often elevated in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, CRNN may be an attractive biomarker for the diagnosis and monitoring of these diseases.

Conclusion:

In conclusion, CRNN is a protein that plays a critical role in maintaining calcium homeostasis. Its regulation of calcium ions is crucial for various cellular functions, including muscle contractions, nerve impulse transmission, and cell signaling. As a result, CRNN is an attractive drug target and biomarker for the diagnosis and treatment of various diseases. Further research is needed to fully understand the role of CRNN in maintaining calcium homeostasis and its potential as a drug and biomarker.

Protein Name: Cornulin

Functions: Promotes cell proliferation, G1/S cell cycle progression and induces expression of the cell cycle regulator CCND1 (PubMed:30009832). Regulates proliferation induced by pro-inflammatory cytokine response via activation of NFKB1 and PI3K/AKT signaling pathways (PubMed:30009832)

The "CRNN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRNN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets